TY - JOUR
T1 - Impact of a novel contrast reduction system on contrast savings in coronary angiography – The DyeVert randomised controlled trial
AU - Desch, Steffen
AU - Fuernau, Georg
AU - Pöss, Janine
AU - Meyer-Saraei, Roza
AU - Saad, Mohammed
AU - Eitel, Ingo
AU - Thiele, Holger
AU - de Waha, Suzanne
PY - 2018/4/15
Y1 - 2018/4/15
N2 - Aims: The most prominent procedure-related and thus modifiable risk factor for contrast-induced acute kidney injury is contrast media (CM) volume. The DyeVert™ system has been designed to reduce the amount of CM. The primary objective of this randomised controlled trial was thus to examine whether the novel DyeVert™ contrast reduction system (Osprey Medical Inc., Minnetonka, MN, USA) leads to a reduction in CM volume in patients undergoing diagnostic coronary angiography. Methods: Patients scheduled for a diagnostic coronary angiogram were randomised to angiography with or without the DyeVert™ system. The primary efficacy endpoint was mean CM volume. Image quality was evaluated by an independent reviewer blinded to treatment allocation. Results: A total of 96 patients underwent randomisation. Baseline characteristics were well balanced between groups. Use of the DyeVert™ system resulted in a significant 41.0% reduction in CM volume (36.9 ± 10.9 mL versus 62.5 ± 12.7 mL, p < 0.001). Image quality using the DyeVert™ system was non-inferior compared to control (p = 0.03). There were no device-related adverse events. Conclusions: The DyeVert™ system leads to significant reduction in CM volume in patients undergoing diagnostic coronary angiography, while maintaining image quality.
AB - Aims: The most prominent procedure-related and thus modifiable risk factor for contrast-induced acute kidney injury is contrast media (CM) volume. The DyeVert™ system has been designed to reduce the amount of CM. The primary objective of this randomised controlled trial was thus to examine whether the novel DyeVert™ contrast reduction system (Osprey Medical Inc., Minnetonka, MN, USA) leads to a reduction in CM volume in patients undergoing diagnostic coronary angiography. Methods: Patients scheduled for a diagnostic coronary angiogram were randomised to angiography with or without the DyeVert™ system. The primary efficacy endpoint was mean CM volume. Image quality was evaluated by an independent reviewer blinded to treatment allocation. Results: A total of 96 patients underwent randomisation. Baseline characteristics were well balanced between groups. Use of the DyeVert™ system resulted in a significant 41.0% reduction in CM volume (36.9 ± 10.9 mL versus 62.5 ± 12.7 mL, p < 0.001). Image quality using the DyeVert™ system was non-inferior compared to control (p = 0.03). There were no device-related adverse events. Conclusions: The DyeVert™ system leads to significant reduction in CM volume in patients undergoing diagnostic coronary angiography, while maintaining image quality.
UR - http://www.scopus.com/inward/record.url?scp=85040560791&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2017.12.107
DO - 10.1016/j.ijcard.2017.12.107
M3 - Journal articles
C2 - 29373136
AN - SCOPUS:85040560791
SN - 0167-5273
VL - 257
SP - 50
EP - 53
JO - International Journal of Cardiology
JF - International Journal of Cardiology
ER -
